Floatz logo

Pembrolizumab

Subcutaneous Panniculitis-Like T-Cell Lymphoma

Northwestern Universitymonoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Subcutaneous Panniculitis-Like T-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Shandong Provincial Hospital
Phase 4BBB
ETOPOSIDE
Shandong Provincial Hospital
Phase 4BBB
(+)-VINCRISTINE
Shandong Provincial Hospital
Phase 4BBB
Ifosfamide
Shandong Provincial Hospital
Phase 4BB
Inno-206
Ruijin Hospital
Phase 4BB

View all 15 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →